Effect of Rivaroxaban in Reducing Radial Artery Occlusion Rate After Transradial Coronary Catheterization

What this Trial Is About

Researchers are studying the effects of Rivaroxaban on treating radial artery occlusion (RAO) that occurs after cardiac catheterization procedures such as angiography and percutaneous coronary intervention (PCI). This is a prospective, randomized, open-label study comparing patients who receive Rivaroxaban with those who do not receive any anticoagulation treatment. The study aims to assess whether Rivaroxaban improves the reopening (patency) of the radial artery at 4 weeks and to compare bleeding and other complications between the groups. Patients diagnosed with RAO through ultrasound after coronary catheterization will be randomly assigned to one of two groups: one group will receive oral Rivaroxaban 20 mg once daily for 4 weeks, while the other group will receive no anticoagulant treatment. The study will monitor patients with ultrasound evaluations of the radial artery at 1, 2, and 4 weeks after the procedure. Clinical assessments of artery patency using pulse palpation and specific tests will also be performed. During the study, participants will undergo ultrasound imaging and clinical evaluations to track artery patency and any bleeding complications using standard bleeding classification systems. Researchers will record data at regular intervals up to 4 weeks after the procedure. The primary outcome is the artery patency at 4 weeks, and secondary outcomes include bleeding events. The study is expected to continue until 2029, with ongoing monitoring of patient responses and safety.

Effect of RIVAroxaban in Radial Artery Occlusion Treatment After Cardiac Catheterization